Financhill
Back

Contineum Therapeutics, Inc. Stock Price Chart

This Tech Company Grew 32,481%...

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Buy
62

CTNM
Contineum Therapeutics, Inc.

Last Price:
$12.34
Seasonality Move:
-24.83%

7 Day Trial

ALL ACCESS PASS

$ 7
  • Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and CTNM is experiencing buying pressure, which is a positive indicator for future bullish movement.

Contineum Therapeutics, Inc. Price Chart Indicators

Moving Averages Level Buy or Sell
8-day SMA: 11.84 Buy
20-day SMA: 11.47 Buy
50-day SMA: 11.32 Buy
200-day SMA: 7.8 Buy
8-day EMA: 11.8 Buy
20-day EMA: 11.62 Buy
50-day EMA: 11.18 Buy
200-day EMA: 7 Buy

Contineum Therapeutics, Inc. Technical Analysis Indicators

Chart Indicators Level Buy or Sell
MACD (12, 26): 0.19 Buy
Relative Strength Index (14 RSI): 57.44 Buy
Chaikin Money Flow: 78678 -
Bollinger Bands Level Buy or Sell
Bollinger Bands (25): (10.81 - 12.21) Buy
Bollinger Bands (100): (9.05 - 12.41) Buy

Contineum Therapeutics, Inc. Technical Analysis

Technical Analysis: Buy or Sell?
8-day SMA:
20-day SMA:
50-day SMA:
200-day SMA:
8-day EMA:
20-day EMA:
50-day EMA:
200-day EMA:
MACD (12, 26):
Relative Strength Index (14 RSI):
Bollinger Bands (25):
Bollinger Bands (100):

Technical Analysis for Contineum Therapeutics, Inc. Stock

Is Contineum Therapeutics, Inc. Stock a Buy?

CTNM Technical Analysis vs Fundamental Analysis

Buy
62
Contineum Therapeutics, Inc. (CTNM) is a Buy

Is Contineum Therapeutics, Inc. a Buy or a Sell?

Contineum Therapeutics, Inc. Stock Info

Market Cap:
317.2M
Price in USD:
12.26
Share Volume:
139.5K

Contineum Therapeutics, Inc. 52-Week Range

52-Week High:
15.25
52-Week Low:
3.35
Buy
62
Contineum Therapeutics, Inc. (CTNM) is a Buy

Contineum Therapeutics, Inc. Share Price Forecast

Is Contineum Therapeutics, Inc. Stock a Buy?

Fundamental Analysis of Contineum Therapeutics, Inc.

Is Contineum Therapeutics, Inc. a good investment?

  • Analysts estimate an earnings decrease this quarter of $0.04 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.15 per share, and a decrease next year of $0.19 per share.

Technical Analysis of Contineum Therapeutics, Inc.

Should I short Contineum Therapeutics, Inc. stock?

* Contineum Therapeutics, Inc. stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.